Kevin O’Brien to Oversee All Sales and Training Activities for the Promotion of Medac Pharma’s First Commercial Product Rasuvo®
Chicago, IL, December 13, 2016
Medac Pharma, Inc., a privately held, commercial-stage specialty pharmaceutical company, announced today the appointment of industry veteran Kevin O’Brien as Vice President of Sales for the company. In this role, Mr. O’Brien will lead all sales and sales training activities for the promotion of Rasuvo® (methotrexate) injection, Medac Pharma’s first commercialized product in the U.S.
Prior to joining Medac Pharma, Mr. O’Brien served as Senior National Sales Director for Sobi, Inc., for nearly six years, where his responsibilities included oversight of U.S. sales, strategy, staffing, sales force effectiveness oversight, sales operations and training. As an original member of the leadership team, he successfully built a high caliber sales and training infrastructure. During his tenure at Sobi, Mr. O’Brien successfully promoted two orphan drugs in the injectable biologics space, including hematology and rheumatology, where he achieved or exceeded forecast sales goals each year. Additionally, Mr. O’Brien led Novartis Pharmaceuticals’ specialty therapeutic areas to exceed the company’s goals. At Novartis, Mr. O’Brien served as National Director for Transplant Sales as well as National Director for Infectious Disease Sales.
Mr. O’Brien formerly held numerous sales leadership positions with Axcan Pharma, Roche Laboratories, Inc. and G.D. Searle and Co.
“We are delighted to have Mr. O’Brien join our team,” said Ms. Terri Shoemaker, President and CEO of Medac Pharma. “Since the launch of Rasuvo in 2014, we have achieved consistent growth each year and are committed to providing patients with rheumatoid arthritis, polyarticular juvenile idiopathic arthritis and psoriasis, a new option to help manage their disease. With the addition of Mr. O’Brien’s expertise, we believe we are well positioned to successfully expand our efforts in reaching new patients and work with partners to in license and deliver new therapeutics to the U.S. market.”
Mr. O’Brien stated, “I’m eager to join Medac Pharma during this exciting time of growth. In addition to helping lead the sales effort for Rasuvo, I am committed to the growth of the company’s commercial enterprise in the U.S. as we expand to new therapeutic areas. The team has developed a successful commercial infrastructure thus far and I am delighted to have the opportunity to have a marked impact in the years ahead.”
For complete prescribing information, including Boxed Warning, and information on Medac Pharma’s CORE Connections program, please visit www.Rasuvo.com.
Medac Pharma, Inc.
Medac Pharma, Inc. is the wholly-owned subsidiary of medac GmbH, a well-known and respected global pharmaceutical company that has been making scientific and therapeutic discoveries for more than 40 years.
Medac Pharma, Inc. is focused on developing therapies with the potential to make meaningful differences in patients’ lives. The company’s approach is to improve existing agents by enhancing the mode of delivery, addressing safety profiles and inventing ways to maximize efficacy.
For more information, please visit www.medacpharma.com.
Tiberend Strategic Advisors, Inc.
email@example.com (212) 375-2694